Research Article
A Non-Invasive Foot-Worn Biomechanical Device for Patients with Hip Osteoarthritis
Michael Drexler1*, Ganit Segal2, Amnon Lahad3, Amir Haim1, Udi Rath1, Amit Mor2, David R Morgensteren4, Moshe Salai1 and Avi Elbaz2
1Department of Orthopedic Surgery, Sourasky Medical Center, Tel Aviv, Israel
2AposTherapy Research Group, Herzliya, Israel
3Department of Family Medicine Hebrew University and Clalit Health Services, Jerusalem, Israel
4The Sports Medicine & Arthroscopy Unit, Orthopedic Department, Hadassah Medical Center, Mount Scopus, Jerusalem
- *Corresponding Author:
- Michael Drexler
Department of Orthopedic Surgery
Sourasky Medical Center
6 Weizmann Street Tel Aviv
64239, Israel
E-mail: [email protected]
Received date: July 22, 2013; Accepted date: November 28, 2013; Published date: December 27, 2013
Citation: Drexler M, Segal G, Lahad A, Haim A, Rath U, et al. (2013) A Non- Invasive Foot-Worn Biomechanical Device for Patients with Hip Osteoarthritis. Surgery Curr Res 3:153. doi:10.4172/2161-1076.1000153
Copyright: © 2013 Drexler M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Objective: The purpose of this study was to evaluate the effect of a biomechanical therapy on the pain, function, quality of life and spatio-temporal gait patterns of patients with hip osteoarthritis (OA).
Design: 60 patients with hip OA were examined before and after twelve weeks of a personalized biomechanical therapy (AposTherapy). Patients were evaluated using the WOMAC questionnaire for pain and function and the SF-36 Health Survey for quality of life, and underwent a computerized gait test.
Results: After twelve weeks of treatment, a significant improvement was found in the patients’ velocity, step length and cadence (P ≤ 0.001). WOMAC-pain, stiffness and function subscales were significantly improved compared to baseline (P ≤ 0.001). SF-36 physical score subscale improved significantly (P=0.007).
Conclusions: Patients with bilateral hip OA treated with AposTherapy for twelve weeks showed statistically and clinically significant improvements in pain, function and gait patterns.
